No Prescription |
 |
 | ||
|
Glinil M Glucovance |
|
| ||
No Prescription » Prescription Drugs 8 » Glinil M Glucovance The combination of glyburide and metformin is used to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in people whose diabetes cannot be controlled by diet and exercise alone. Glyburide belongs to a class of drugs called sulfonylureas and metformin is in a class of drugs called biguanides. Glyburide lowers blood sugar by stimulating the pancreas the organ that makes insulin. Insulin helps control blood sugar levels. The pancreas must produce insulin for this medication to work. Metformin helps your body regulate the amount of glucose (sugar) in your blood. It decreases the amount of glucose you get from your diet and the amount made by your liver. It also helps your body use its own insulin more effectively. Glyburide and metformin are not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Buy Glinil M Glucovance and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Glinil M Glucovance: Product Type: Prescription Drugs 8 Glinil M ( Glucovance Generic Glyburide & Metformin ) Glinil M (Glucovance Generic Glyburide & Metformin) Glucovance Generic Glyburide & Metformin 5/500mg 100 Tablets 200 Tablets 400 Tablets Glucovance Generic Glyburide & Metformin Glinil M
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
